Related Experiment Video

Updated: Mar 14, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with

Ruey-Hsing Chou1,2,3, Po-Hsun Huang1,2,3, Chien-Yi Hsu2,3,4,5

  • 1Division of Cardiology, Department of Medicine Taipei Veterans General Hospital, Taipei, 11217, Taiwan.

Scientific Reports
|September 22, 2016
PubMed

Insights

Fibroblast growth factor 21 (FGF21) is linked to diastolic heart failure. Higher FGF21 levels predict adverse cardiac events, suggesting its role in the condition's development.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Fibroblast growth factor 21 (FGF21) is known to regulate glucose and lipid metabolism.
  • Previous research indicated FGF21 can reduce cardiac hypertrophy.
  • The role of FGF21 in diastolic heart failure remained unclear.

Purpose of the Study:

  • To investigate the association between FGF21 and diastolic heart failure.
  • To determine if FGF21 levels can predict adverse cardiac events in patients with diastolic dysfunction.

Main Methods:

  • Plasma FGF21 and NT-pro-BNP levels were measured in 95 patients with diastolic dysfunction and 143 controls.
  • Echocardiography assessed left ventricular (LV) function and diastolic parameters.
  • Patients were followed for 1 year for cardiac readmission or death.

Main Results:

  • Circulating FGF21 levels correlated with echocardiographic measures of diastolic function and LV end-diastolic pressure.
  • FGF21 was significantly associated with diastolic dysfunction.
  • Both FGF21 and NT-pro-BNP levels predicted 1-year adverse cardiac events.

Conclusions:

  • FGF21 may play a role in the pathophysiology of diastolic heart failure.
  • Plasma FGF21 levels are a potential biomarker for diastolic dysfunction and adverse cardiac outcomes.

More Related Videos

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
705
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
498